Fidelis Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Fidelis Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$913K	Buy	5,408 +563	+12%	+$96.3K	0.07%	223
2025 Q4	$818K	Buy	4,845 +30	+0.6%	+$4.87K	0.06%	233
2025 Q3	$695K	Sell	4,815 -237	-5%	-$32.4K	0.05%	250
2025 Q2	$664K	Buy	5,052 +43	+0.9%	+$5.28K	0.06%	228
2025 Q1	$617K	Sell	5,009 -109	-2%	-$14.8K	0.07%	220
2024 Q4	$706K	Sell	5,118 -135	-3%	-$19K	0.07%	207
2024 Q3	$747K	Buy	5,253 +409	+8%	+$59.2K	0.09%	189
2024 Q2	$669K	Buy	4,844 +1,610	+50%	+$215K	0.1%	176
2024 Q1	$444K	Buy	+3,234	New	+$442K	0.07%	224

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelis Capital Partners's IBB Position: Q1 2026 in Review

Fidelis Capital Partners increased its iShares Biotechnology ETF (IBB) stake by 12% in Q1 2026, buying an estimated $96.3K and bringing the position to 5,408 shares worth $913K. The position accounts for 0.07% of the portfolio, ranked #223.

Fidelis Capital Partners first reported a position in IBB in Q1 2024 and has held it in 9 quarters since. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Fidelis Capital Partners held 5,408 shares of iShares Biotechnology ETF worth $913K as of Q1 2026.
Fidelis Capital Partners bought 563 iShares Biotechnology ETF shares in Q1 2026, an estimated $96.3K.
iShares Biotechnology ETF made up 0.07% of Fidelis Capital Partners's portfolio in Q1 2026, its #223 holding.
Fidelis Capital Partners first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 9 quarters since.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.